Drug Delivery, 2022 Arsenic trioxide (As2O3, ATO) has limited therapeutic benefit to treat solid tumors, whether used alone or in combination. Nanoscale drug delivery vehicles have great potential to overcome the limitation of the utility of ATO by rapid renal clearance and
Qiu-Chen Bi +10 more
doaj +1 more source
Emerging Effects of Sevelamer in Chronic Kidney Disease
Kidney & Blood Pressure Research, 2013 Sevelamer, a non-absorbable anion exchange resin, is used to control hyperphosphatemia in chronic kidney disease (CKD) by binding to dietary phosphate in the gastrointestinal tract.
Ryota Ikee +4 more
doaj +1 more source
The intestine and the kidneys : a bad marriage can be hazardous [PDF]
, 2015 The concept that the intestine and chronic kidney disease influence each other, emerged only recently. The problem is multifaceted and bidirectional. On one hand, the composition of the intestinal microbiota impacts uraemic retention solute production ...
Glorieux, Griet, Vanholder, Raymond
core +1 more source
Colonic Mass Secondary to Sevelamer-associated Rectal Ulcer
The Korean Journal of Gastroenterology, 2021 The phosphorous balance is clinically important in increasing the long-term outcomes and preventing complications of end-stage renal disease. Sevelamer is a phosphate binder used widely to regulate hyperphosphatemia.
Jin Hee Lee +10 more
doaj +1 more source
Phosphorus binders: preferences of patients on hemodialysis and its impact on treatment compliance and phosphorus control [PDF]
, 2010 Introducción: En la actualidad disponemos de un amplio abanico de captores del fósforo (CF), pero sabemos poco acerca de las preferencias de los pacientes y de su repercusión sobre el cumplimiento del tratamiento y el control de los niveles de fósforo ...
Arenas Jiménez, María Dolores +5 more
core +2 more sources
Effect of sevelamer on serum phosphorus levels in chronic kidney disease and hemodialysis patients; a systematic review and meta-analysis [PDF]
Journal of NephropathologyIntroduction: Hyperphosphatemia is an independent risk factor for mortality in chronic kidney disease (CKD) patients. Objectives: This systematic review and meta-analysis aimed to investigate the effect of Sevelamer on serum phosphorus levels in CKD and ...
Farshad Gharebakhshi +8 more
doaj +1 more source
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide. [PDF]
, 2014 Sucroferric oxyhydroxide (VELPHORO(®)) is a polynuclear iron-based phosphate binder recently approved for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). As a number of the available phosphate binders do not provide the
Cozzolino, M. +4 more
core +1 more source
Frontiers in Medicine, 2021 Patients with end-stage renal disease (ESRD) present alterations in mineral and bone metabolism. Hyperphosphatemia in ESRD is considered an independent risk factor for cardiovascular disease (CVD), increasing morbidity, and mortality.
Elodia Nataly Díaz-De la Cruz +8 more
doaj +1 more source
Clinical protocol and therapeutic guidelines for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease [PDF]
, 2013 Universidade de São Paulo Faculdade de Medicina Serviço de NefrologiaUniversidade Federal de São Paulo (UNIFESP) Serviço de NefrologiaPontifícia Universidade Católica do Paraná Escola de MedicinaUniversidade Federal da Bahia Departamento de Medicina ...
Barreto, Fellype Carvalho +10 more
core +9 more sources
Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease [PDF]
, 2016 Secondary hyperparathyroidism (SHPT) is a common complication of CKD and is part of the chronic kidney disease-mineral bone disorder (CKD-MBD). SHPT is associated with increased risk of fracture and mortality, thus SHPT control is recommended as kidney ...
Khwaja, A., Salam, S.N., Wilkie, M.E.
core +1 more source